Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients

被引：38

作者：

Bostom, AG

Shemin, D

Yoburn, D

Fisher, DH

Nadeau, MR

Selhub, J

机构：

[1] Vitamin Bioavailability Laboratory, Jean Mayer USDA Hum. Nutr. Res. C., Tufts New England Medical Center, Boston, MA 02111

[2] Division of Renal Diseases, Rhode Island Hospital, Providence, RI

[3] Center for Bioanalytical Research, University of Kansas, Lawrence, KS

来源：

ATHEROSCLEROSIS | 1996年 / 120卷 / 1-2期

关键词：

Hyperhomocysteinemia; N-acetylcysteine; Renal failure; Treatment;

D O I：

10.1016/0021-9150(95)05705-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hyperhomocysteinemia refractory to standard B-vitamin supplementation treatment persists in ≥ 75% of maintenance dialysis patients, potentially increasing their risk for atherothrombotic sequelae. We examined whether predialysis administration of oral N-acetylcysteine (NAC), which acutely increases the non-protein bound, dialyzable fraction of plasma homocysteine, might augment the homocysteine-lowering effect of dialysis therapy. Predialysis and postdialysis total plasma homocysteine levels were determined on a control day, and on a day in which oral NAC (1200 mg) was administered predialysis in n = 11 maintenance hemodialysis patients. Although NAC treatment had no significant effect on hemodialysis removal of plasma homocysteine (P = 0.594), we observed a 16% reduction (P = 0.033) in non-fasting prehemodialysis total plasma homocysteine on the NAC treatment vs. non-treatment day. Longer term, placebo-controlled confirmation of this finding will be required to evaluate the possible chronic homocysteine-lowering efficacy of NAC treatment in hemodialysis patients.

引用

页码：241 / 244

页数：4

共 17 条

[1]

Maiorca R., Cancarini G.C., Brunori G., Camerini C., Manili L., Morbidity and mortality of CAPD and hemodialysis, Kidney Int, 43, (1993)

[2]

Parfrey P.S., Harnett J.D., Long term cardiac morbidity and mortality during dialysis therapy, Adv Nephrol, 23, (1994)

[3]

Selhub J., Jacques P.F., Bostom A.G., Et al., Association between plasma homocysteine concentrations and extracranial carotid artery stenosis, N Engl J Med, 332, (1995)

[4]

Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullman D., A prospective study of plasma homocyst(e)ine and the risk of myocardial infarction in us physicians, J Am Med Assoc, 268, (1992)

[5]

Arnesen E., Refsum H., Bonaa K.H., Ueland P.M., Forde O.H., Nordrehaug J.E., Serum total homocysteine and coronary heart disease, Int J Epidemiol, 24, (1995)

[6]

Bostom A.G., Shemin D., Lapane K.L., Et al., Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case control study, Atherosclerosis, 114, (1995)

[7]

Arnadottir M., Brattstrom L.A., Simonsen O., Et al., The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients, Clin Nephrol, 40, (1993)

[8]

Janssen M.J.F.M., Stehouwer C.D.A., Van Den Berg M., Van Der Meulen J., Boers G.H.J., Donker A.J.M., Folic acid lowers elevated homocysteine levels in chronic dialysis patients, J Am Soc Nephrol, 4, (1993)

[9]

Guldener C., Janssen M.J.F.M., Van Den Berg M., Stiuwher C.D.A., Donker A.J.M., Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients, Perit Dial Int, 14, 1 SUPPL., (1994)

[10]

Bostom A.G., Shemin D., Nadeau M.R., Shih V., Stabler S.P., Allen R.H., Selhub J., Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation, Atherosclerosis, 113, (1995)

← 1 2 →